This study examined also biomarkers of immune response in BRCA1-, BRCA2- and PALB2-mutated pancreatic cancers and showed that BRCA1- and BRCA2- but not PALB2-mutated cancers had a higher prevalence of PD-L1-positive staining (defined as staining of >1% cancer cells in immunohistochemistry) than wild type counterparts. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.